ATEC (ATEC) Q2 2023: Lateral Franchise Drives 41% Surgical Growth, Setting Standard for Spine Market Expansion
ATEC’s lateral spine focus powered a step-change in surgical growth and operating leverage, with margin expansion reflecting disciplined execution and clinical distinction. The company’s deep procedural innovation and ecosystem approach are translating into surgeon adoption, while cross-segment integration and automation initiatives position ATEC for sustained outperformance and sector leadership.
Summary
- Lateral Leadership Accelerates Adoption: Deep procedural expertise and innovation in lateral spine surgery are driving outsized share gains.
- Operating Leverage Emerges: Margin expansion reflects scalable model and disciplined reinvestment in core innovation engines.
- Automation and Informatics Foundation: EOS and robotics integration set up multi-year data and workflow advantages.
Business Overview
ATEC (Alphatec Holdings) is a pure-play, innovation-driven spine surgery company focused on creating procedural solutions for complex spine pathologies. The business generates revenue from surgical implants, enabling technologies, and informatics platforms, with major segments including surgical revenue (implants, instrumentation, biologics) and EOS imaging (preoperative planning and surgical workflow automation). The company’s growth is anchored in its lateral spine franchise, procedural innovation, and expanding technology ecosystem.
Performance Analysis
ATEC delivered a standout quarter, with total revenue up 39% year-over-year and surgical revenue up 41%—both outpacing the low-single-digit spine market baseline. Growth was propelled by a 32% increase in procedural volume and a 7% rise in revenue per procedure, driven by a mix shift toward more complex, higher-value procedures such as PTP (Prone Transpsoas) and LTP (Lateral Transpsoas), as well as expanding biologics attachment rates. EOS imaging revenue rose 24%, reflecting solid execution on installations and service backlog reduction.
Margin expansion was pronounced, with non-GAAP gross margin up 340 basis points year-over-year and adjusted EBITDA turning positive ahead of plan. Operating leverage came from improved royalty rates, favorable sales mix, and infrastructure scalability, with SG&A as a percentage of sales dropping by 850 basis points. R&D spend remained robust at 11% of sales, reflecting ongoing investment in robotics and informatics platforms. Cash use was concentrated in sales-generating assets and inventory to support accelerated growth, while leverage improvements validated management’s long-term profitability thesis.
- Volume-Driven Outperformance: Strong surgeon adoption and procedural expansion powered both volume and revenue-per-case gains.
- Clinical Distinction Pays Off: Investments in lateral, expandable implants, and biologics are translating directly into market share capture.
- Operating Leverage Materializes: Margin expansion and positive adjusted EBITDA signal a scalable, disciplined growth engine.
ATEC’s performance demonstrates the compounding effect of procedural innovation, surgeon education, and ecosystem integration, positioning the company to further expand its share in a market that is otherwise growing slowly.
Executive Commentary
"Our growth has been fueled by our spine focus. The commitment of clinical distinction continues. There's nothing better than being aligned with your customer. And, you know, spine surgeons commit their career, their vocation to spine surgery. So being aligned with them in terms of being spine focus is big."
Pat Miles, Chairman and CEO
"Continued top-line growth and disciplined execution is delivering results. And this quarter's performance reinforces our confidence in achieving the long-term profitability goals we've committed to."
Todd Koning, Chief Financial Officer
Strategic Positioning
1. Lateral Franchise as Growth Engine
ATEC’s lateral solutions, particularly PTP and LTP, are the primary drivers of outsized growth, with surgeon adoption and procedure expansion leading to higher revenue per case. The company’s decades of experience, proprietary SafeOp neuromonitoring, and targeted surgeon education create a defensible moat, as competitors struggle to replicate ATEC’s know-how and procedural sophistication.
2. Ecosystem and Informatics Integration
The EOS imaging platform is being integrated into the surgical workflow, with automated alignment, 3D modeling, and surgical planning slated for mid-2024. This end-to-end informatics approach will support predictive analytics, patient-specific implants, and post-op outcome tracking, creating a data-rich feedback loop and future-proofing ATEC’s offering.
3. Robotics and Navigation Platform
Acquisition and integration of navigation-enabled robotics are on track, with initial regulatory milestones expected late 2023 and full workflow integration by 2025. The company’s focus on a small, cost-effective footprint and flexible commercial models (purchase, lease, volume-based) should accelerate adoption and lower barriers for hospital partners.
4. Distribution and Geographic Expansion
ATEC is aggressively filling geographic gaps and leveraging market uncertainty to attract top sales talent and expand its distribution footprint. Same-store sales growth of 38% in established territories demonstrates the strength of the model, with international expansion (notably Australia, New Zealand, and early moves in Japan) providing additional optionality.
5. Portfolio Breadth and Pipeline
While cervical motion preservation remains an acknowledged portfolio gap, the company’s innovation engine is rapidly addressing adjacent opportunities, including deformity solutions, corpectomy, and 3D-printed implants. Nine regulatory submissions in the quarter reflect a high-velocity R&D cadence and readiness to obsolete legacy offerings.
Key Considerations
This quarter highlights ATEC’s ability to translate clinical innovation into commercial momentum, with operating leverage and surgeon adoption reinforcing the sustainability of its growth trajectory. Investors should assess:
Key Considerations:
- Surgeon Training as Leading Indicator: Over 150 surgeons trained in Q2, with 25% new to lateral techniques, supporting future procedural adoption and utilization.
- Revenue Mix Shift to High-Complexity Cases: Multi-level and more complex surgeries (enabled by LTP and ALIF access) drive higher revenue per procedure and deepen clinical engagement.
- EOS Cross-Sell Opportunity Still Nascent: Cross-selling ATEC implants into EOS imaging accounts remains early, with automation and informatics upgrades expected to unlock incremental growth in 2024 and beyond.
- Operating Model Scalability: Margin expansion and positive EBITDA reflect a scalable business model, with reinvestment discipline supporting both near-term growth and long-term profitability goals.
Risks
Key risks include the pace and breadth of surgeon adoption (which varies by geography and surgeon experience), competitive responses in lateral and robotics, and the execution risk around integrating informatics and automation into the surgical workflow. The company’s reliance on continued innovation and surgeon loyalty means any misstep in training, product rollout, or clinical outcomes could impact momentum. International expansion, while promising, also introduces regulatory and operational complexity.
Forward Outlook
For Q3 and Q4, ATEC guided to:
- Continued low-20% procedure volume growth for the remainder of 2023
- High single-digit growth in average revenue per surgery for the full year
For full-year 2023, management raised guidance:
- Total revenue of approximately $462 million (32% growth)
- Surgical revenue of $404 million (33% growth)
- EOS revenue of $58 million (21% growth)
- Adjusted EBITDA of $2 million, reflecting 840 basis points of margin expansion
Management highlighted several factors that support this trajectory:
- Surgeon training and adoption trends that drive procedural growth and utilization ramp
- Operating leverage from both variable selling expense improvements and infrastructure scalability
Takeaways
ATEC’s Q2 results mark a clear inflection point, with lateral procedural innovation and ecosystem integration driving both top-line growth and operating leverage. The company’s ability to scale its model while maintaining high clinical distinction is translating into share gains and a differentiated competitive position.
- Lateral Franchise Momentum: The depth of ATEC’s lateral expertise and SafeOp neuromonitoring are proving difficult for competitors to match, fueling adoption and revenue mix improvement.
- Scalable Innovation Engine: High R&D velocity, coupled with disciplined reinvestment and margin expansion, validate the company’s long-term growth and profitability thesis.
- Strategic Watchpoints: Investors should monitor EOS automation milestones, robotics integration, and cross-sell execution as key drivers of future revenue acceleration and margin leverage.
Conclusion
ATEC’s Q2 performance demonstrates the power of clinical focus, procedural innovation, and ecosystem integration in driving durable growth and operating leverage. With a robust innovation pipeline and expanding distribution, ATEC is positioned to remain a standard bearer in spine surgery and to unlock further value in the years ahead.
Industry Read-Through
ATEC’s results reinforce a broader shift in the spine market toward procedural specialization, data-driven workflow integration, and surgeon-centric innovation. The outperformance of lateral procedures and rapid adoption of enabling technologies highlight the limits of commoditization in complex surgical markets. Competitors lacking deep procedural expertise or integrated informatics platforms may face increasing share loss and margin pressure. The emphasis on automation, surgeon training, and flexible robotics commercialization models is likely to shape future industry dynamics and capital allocation across the spine and broader orthopedic technology sectors.